

Ⅲ. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ
鈴木義之	高齢者・合併症例のインフォームド・コンセント	銭谷 幹男 八橋 弘 柴田 実	C型肝炎のベスト治療インターフェロンを中心に	医学書院	東京	2009	36-37
平松直樹、小瀬嗣子、林紀夫	C型肝炎に対するPeg-IFN/RBV治療と新規抗ウイルス治療薬の開発状況。	林紀夫、日比紀文、上西紀夫、下瀬川徹	Annual review 2009 消化器	中外医学社	東京	2009	117-128
平松直樹、林紀夫	C型肝炎「肝疾患の診療」	白鳥敬子、菅野健太郎、坪内博仁、日比紀文	消化器研修ノート	診断と治療社	東京	2009	444-449
小瀬嗣子、平松直樹	ペグインターフェロン・リバビリン併用療法。	三田英治、加藤道夫	肝炎診療バイブル	メディカ出版	大阪	2009	81-86

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kusakabe A, Tanaka Y, Mochida S, Nakayama N, Inoue K, Sata M, Isoda N, Kang J. H, Sumino Y, <u>Yatsuhashi H</u> , Takikawa Y, Kaneko S, Yamada G, Karino Y, <u>Tanaka E</u> , Kato J, Sakaida I, Izumi N, Sugauchi F, Nojiri S, Joh T, Miyakawa Y, Mizokami M	Case-control study for the identification of virological factors associated with fulminant hepatitis B.	Hepatol Res	39	648-656	2009

Matsumoto A, <u>Tanaka E</u>	Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: some concerns (reply).	Hepatology	49	2125	2009
Matsuura K, Tanaka Y, <u>Hige S</u> , Yamada G, Murawaki Y, Komatsu M, Kuramitsu T, Kawata S, <u>Tanaka E</u> , Izumi N, Okuse C, Kakumu S, Okanoue T, Hino K, Hiasa Y, Sata M, Maeshiro T, Sugauchi F, Nojiri S, Joh T, Miyakawa Y, Mizokami M	Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A.	J Clin Microbiol	47	1476-1483	2009
Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, <u>Tanaka E</u> , Onji M, <u>Toyota J</u> , Chayama K, Yoshioka K, Izumi N, Akuta N, Kumada H	Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.	J Gastroenterol	44	952-963	2009
Tamura Y, Igarashi M, Suda T, Wakai T, Shirai Y, Umemura T, <u>Tanaka E</u> , Kakizaki S, Takagi H, Hiasa Y, Onji M, Aoyagi Y	Fucosylated Fraction of Alpha-Fetoprotein as a Predictor of Prognosis in Patients with Hepatocellular Carcinoma After Curative Treatment.	Dig Dis Sci			2009

Tanaka N, Horiuchi A, Yamaura T, Komatsu M, Yokoyama T, Okaniwa S, Nagaya T, Yoshizawa K, Kiyosawa K, Aoyama T, <u>Tanaka E</u>	Efficacy and safety of addition of minor bloodletting (petit phlebotomy) in hepatitis C virus-infected patients receiving regular glycyrrhizin injections.	J Gastroenterol	44	577-582	2009
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, <u>Hige S</u> , Ito Y, Mita E, <u>Tanaka E</u> , Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M	Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.	Nat Genet	41	1105-1109	2009
Umemura T, Ichijo T, Yoshizawa K, <u>Tanaka E</u> , Kiyosawa K	Epidemiology of hepatocellular carcinoma in Japan.	J Gastroenterol	44	102-107	2009
Okuyama W, Tanaka N, Nakajima T, <u>Tanaka E</u> , Kiyosawa K, Gonzalez F J, Aoyama T	Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress.	J Hepatol	50	1236-1246	2009

Joshita S, Ichijo T, Suzuki F, Yokoyama T, Sugiyama Y, Fukushima M, Kamijo A, Komatsu M, Umemura T, Yoshizawa K, Miyagawa S, <u>Tanaka E</u>	A case of well-differentiated cholangiolocellular carcinoma visualized with contrast- enhanced ultrasonography using Sonazoid.	Hepatol Res	39	207-212	2009
Fujiwara K, Kojima H, Yonemitsu Y, Yasui S, <u>Imazeki F</u> , Miki M, Suzuki K, Sakaida I, Okita K, <u>Tanaka</u> <u>E</u> , Omata M, Yokosuka O	Phylogenetic analysis of hepatitis A virus in sera from patients with hepatitis A of various severities.	Liver Int	29	838-845	2009
Nagaya T, Tanaka N, Kamijo A, Joshita S, Nakazawa K, Miyabayashi H, Yoneda S, Ito T, Komatsu M, <u>Tanaka E</u> , Kitano K	Primitive neuroectodermal tumor as a differential diagnosis of CD56-positive tumors in adults.	Intern Med	48	1267- 1272	2009
Umemura T, Katsuyama Y, Hamano H, Kitahara K, Takayama M, Arakura N, Kawa S, <u>Tanaka E</u> , Ota M	Association analysis of Toll- like receptor 4 polymorphisms with autoimmune pancreatitis.	Hum Immunol	70	742-746	2009

Tsuruta G, Tanaka N, Hongo M, Komatsu M, Horiuchi A, Hamamoto K, Iguchi C, Nakayama Y, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Aoyama T, <u>Tanaka E</u>	Nonalcoholic fatty liver disease in Japanese junior high school students: its prevalence and relationship to lifestyle habits.	J Gastroenterol	in press		2010
Tsutsui M, Tanaka N, Kawakubo M, Sheena Y, Horiuchi A, Komatsu M, Nagaya T, Joshita S, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Aoyama T, <u>Tanaka E</u> , Sano K	Serum Fragmented Cytokeratin 18 Levels Reflect the Histologic Activity Score of Nonalcoholic Fatty Liver Disease More Accurately Than Serum Alanine Aminotransferase Levels.	J Clin Gastroenterol	in press		2010
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, <u>Suzuki Y</u> , Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.	A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: Amino acid substitutions in HCV core region as predictor of sustained virological response	Journal of Medical Virology	81	452-458	2009
Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, <u>Suzuki Y</u> , Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.	Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil	Intervirology	51 (6)	385-393	2009

Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, <u>Suzuki Y</u> , Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, _ Kumada H.	Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.	Journal of Medical Virology	81	1032-1039	2009
Arase Y, Suzuki F, <u>Suzuki Y</u> , Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Saitoh S, Ikeda K, Kobayashi M, Kumada H.	Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.	Hepatology	49	739-744	2009
Arase Y, Suzuki F, Akuta N, Sezaki H, <u>Suzuki Y</u> , Kawamura Y, Kobayashi M, Hosaka T, Yatsuji H, Hirakawa M, Saitoh S, Ikeda K, Kobayashi M, Kumada H.	Combination Therapy of Peginterferon and Ribavirin for Hepatitis C Patients with Genotype 1b and Low-virus Load.	Internal Medicine	48	253-258	2009
Ikeda K, Arase Y, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, <u>Suzuki Y</u> , Kumada H.	Necessities of interferon therapy in elderly patients with hepatitis C.	American Journal of Medicine	122	479-486	2009

Ikeda K, Kobayashi M, Someya T, Saitoh S, Hosaka T, Akuta N, Suzuki F, <u>Suzuki Y</u> , Arase Y, Kumada H.	Occult hepatitis B virus infection inceases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study.	Journal Viral Hepatitis	16	437-443	2009
Kawamura Y, Ikeda K, Hirakawa M, Hosaka T, Kobayashi M, Saitoh S, Yatsuji H, Sezaki H, Akuta N, Suzuki F, <u>Suzuki Y</u> , Arase Y, Kumada H.	Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin.	Hepatology Resarch	39	346-354	2009
Kobayashi M, Ikeda K, Kawamura Y, Yatsuji H, Hosaka T, Sezaki H, Akuta N, Suzuki F, <u>Suzuki Y</u> , Saitoh S, Arase Y, Kumada H.	High serum Alpha Fetoprotein and Des-gamma-Carboxy Prothrombin Level Predict Poor Prognosis after Radiofrequency Ablation of Hepatocellular carcinoma.	Cancer	115	571-580	2009
Sezaki H, Suzuki F, Akuta N, Yatsuji H, Hosaka T, Kobayashi M, <u>Suzuki Y</u> , Arase Y, Ikeda K, Miyakawa Y, Kumada H.	An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with C virus genotype 1b in high viral loads.	Intervirolgy	52	43-48	2009
Sezaki H, Suzuki F, Kawamura Y, Yatsuji H, Hosaka T, Akuta N, Kobayashi M, <u>Suzuki Y</u> , Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H.	Poor Response to Pegylated Interferon and Ribavirin in Aged Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads.	Dig Dis Sci	54	1317- 1324	2009

Hosaka T, Ikeda K, Kobayashi M, Kawamura Y, Sezaki H, Akuta N, Suzuki F, <u>Suzuki Y</u> , Arase Y, Kumada H.	Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma.	Liver International	29	736-742	2009
Moriyama D, Kobayashi M, Ikeda K, Kawamura Y, Saneto H, Yatsuji H, Hosaka T, Sezaki H, Akuta N, <u>Suzuki Y</u> , Suzuki F, Kumada H.	Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus related cirrhosis and thrombocytopenia.	Hepatology Research	39	439-447	2009
<u>Suzuki Y</u> , Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Miyakawa Y, Kumada H.	Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: Histological improvement or entecavir resistance?	Journal of Gastroenterology and Hepatology	24	429-435	2009
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, <u>Suzuki Y</u> , Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Association of amino acid substitution pattern in core protein of hepatitis C virus Genotype 2a high viral load and virological response to interferon-ribavirin combination therapy.	Intervirology	52	301-309	2009

保坂哲也、鈴木文孝、小林正宏、平川美晴、川村祐介、八辻寛美、瀬崎ひとみ、芥田憲夫、鈴木義之、斉藤聡、荒瀬康司、池田健次、小林万利子、熊田博光.	核酸アナログ療法中のB型関連肝癌に対する肝癌再発予測マーカーとしてHBsAg関連抗原の有用性	肝臓	50(10)	588-589	2009
Arase Y, Suzuki F, Sezaki H, Kawamura Y, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Yatsuji H, Hirakawa M, Kobayashi M, Saitou S, Ikeda K Kumada H.	The efficacy of interferon- β monotherapy for elderly patients with type C hepatitis of genotype 2.	Internal Medicine	48	1337-1342	2009
Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Saitou S, Ikeda K, Kobayashi M, Kumada H, Kobayashi T.	Losartan reduces the onset of type2 diabetes in hypertensive Japanese patients with chronic hepatitis C.	Journal of Medical Virology	81	1584-1590	2009
Ogura S, Akuta N, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Kobayashi M, Suzuki F, Suzuki Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Virological and Biochemical Features in Elderly HCV Patients with Hepatocellular Carcinoma: Amino acid substitutions in HCV Core region as Predictors of Mortality after First Treatment	Intervirolgy	52	179-188	2009

Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, Kumada H.	Rapid loss hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks.	Hepatology Research	39	1056-1063	2009
Kobayashi M, Suzuki F, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kumada H.	Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels.	Scand J Gastroenterol	44	975-983	2009
Hashimoto Y, Suzuki F, Hirakawa M, Kawamura Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki Y, Kobayashi M, Arase Y, Ikeda K, Kumada H.	Clinical and virological effects of long-term (over 5 years) lamivudine therapy	Journal of Medical Virology	in press	in press	2009
Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, Kumada H.	The efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients.	Journal of Gastroenterology and Hepatology	In press	In press	2009

Suzuki Y, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Miyakawa Y, Kumada H	Association of HLA-DR14 with Treatment Response in Japanese Patients with Autoimmune Hepatitis	Dig Dis Sci	In press	In press	2010
Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, Kumada H.	Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3- 4A protease inhibitor telaprevir.	Journal of clinical virology	47(1)	76-79	2010
Kobayashi M, Suzuki F, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kumada H.	Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b.	Journal of Medical Virology	82	41-48	2010
Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H.	Development of HCC in patients receiving adefovir dipiroxil for lamivudine- resistant hepatitis B virus mutants.	Hepatology Research	In press	In press	2010

Kobayashi M, Suzuki F, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kumada H.	Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum alanine aminotransferase during lamivudine treatment in hepatitis B.	Hepatology Reserch	In press	In press	2010
Kurokawa M, Hiramatsu N, Oze T, Mochizuki K, Yakushijin T, Kurashige N, Inoue Y, Igura T, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Yoshihara H, Inoue A, Imai Y, Kato M, Kiso S, Kanto T, Takehara T, Kasahara A, Hayashi N	Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis.	Hepatol Res.	39(5)	432-8.	2009

Oze T, <u>Hiramatsu N</u> , Yakushijin T, Kurokawa M, Igura T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N	Peginterferon alfa-2b affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with pegylated interferon alfa-2b plus ribavirin.	J Viral Hepat.	16(8)	578-85.	2009
<u>Hiramatsu N</u> , Oze T, Yakushijin T, Inoue Y, Igura T, Mochizuki K, Imanaka K, Kaneko A, Oshita M, Hagiwara H, Mita E, Nagase T, Ito T, Inui Y, Hijioka T, Katayama K, Tamura S, Yoshihara H, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N	Ribavirin dose reduction raises relapse rate dose- dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2b plus ribavirin.	J Viral Hepat.	16(8)	586-94	2009

Kurashige N, <u>Hiramatsu N</u> , Ohkawa K, Yakushijin T, Kiso S, Kanto T, Takehara T, Kasahara A, Doi Y, Yamada A, Oshita M, Mita E, Hagiwara H, Nagase T, Yoshihara H, Hayashi E, Imai Y, Kato M, Kashihara T, Hayashi N	Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine- resistant chronic hepatitis B.	J Gastroenterol.	44(6)	601-7	2009
Kurashige N, Ohkawa K, <u>Hiramatsu N</u> , Yakushijin T, Mochizuki K, Oze T, Kiso S, Kanto T, Takehara T, Kasahara A, Doi Y, Yamada A, Fukuda K, Oshita M, Mita E, Fukui H, Nagase T, Yoshihara H, Imai Y, Kato M, Kashihara T, Hayashi N	Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance.	J Gastroenterol.	44(8)	864-70	2009
Itose I, Kanto T, Kakita N, Takebe S, Inoue M, Higashitani K, Miyazaki M, Miyatake H, Sakakibara M, <u>Hiramatsu N</u> , Takehara T, Kasahara A, Hayashi N	Enhanced ability of regulatory T cells in chronic hepatitis C patients with persistently normal alanine aminotransferase levels than those with active hepatitis.	J Viral Hepat.	16(12)	844-52	2009

Hikita H, Takehara T, Shimizu S, Kodama T, Li W, Miyagi T, Hosui A, Ishida H, Ohkawa K, Kanto T, <u>Hiramatsu N</u> , Yin XM, Hennighausen L, Tatsumi T, Hayashi N	Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver.	Hepatology	50(4)	1217-26	2009
Kurashige N, Ohkawa K, <u>Hiramatsu N</u> , Oze T, Yakushijin T, Mochizuki K, Hosui A, Miyagi T, Ishida H, Tatsumi T, Kanto T, Takehara T, Hayashi N	Two types of drug-resistant hepatitis B viral strains emerging alternately and their susceptibility to combination therapy with entecavir and adefovir.	Antivir Ther.	14(6)	873-7	2009
Kohga K, Takehara T, Tatsumi T, Miyagi T, Ishida H, Ohkawa K, Kanto T, <u>Hiramatsu N</u> , Hayashi N	Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.	Cancer Res.	69(20)	8050-57	2009
Hikita H, Takehara T, Kodama T, Shimizu S, Hosui A, Miyagi T, Tatsumi T, Ishida H, Ohkawa K, Li W, Kanto T, <u>Hiramatsu N</u>	BH3-only protein bid participates in the Bcl-2 network in healthy liver cells.	Hepatology	50(6)	1972-80	2009
西口修平、泉並 木、日野啓輔、 鈴木文孝、熊田 博光、伊藤義人 、朝比奈靖浩、 田守昭博、平松 直樹、林紀夫、 工藤正俊	日本肝臓学会コンセンサス神戸 2009 : C型肝炎の診断と治療	肝臓	50	665-677	2009

林紀夫、平松直樹、小瀬嗣子.	C型肝炎に対するインターフェロン治療と抗ウイルス剤.	日本医師会雑誌	138(6)	1089-1094	2009
Shindo M, Chayama K, Mochida S, <u>Toyota J</u> , Tomita E, Kumada H, Yokosuka O, Sata M, Hayashi N, Suzuki K, Okanoue T, Tsubouchi H, Ishikawa H, Seriu T, Omata M	Antiviral activity, dose-response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naïve Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial	Hepatol Int			2009
Hiraga N, Imamura M, Hatakeyama T, Kitamura S, Mitsui F, Tanaka S, <u>Tsuge M</u> , Takahashi S, Abe H, Maekawa T, Ochi H, Tateno C, Yoshizato K, Wakita T, Chayama K.	Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice.	Journal of Hepatology	51	1046-54	2009
Abe H, Ochi H, Maekawa T, Hatakeyama T, <u>Tsuge M</u> , Kitamura S, Kimura T, Miki D, Mitsui F, Hiraga N, Imamura M, Fujimoto Y, Takahashi S, Nakamura Y, Kumada H, Chayama K.	Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection.	Hepatol Res	39	1159-68	2009

Noguchi C, Imamura M, <u>Tsuge M</u> , Hiraga N, Mori N, Miki D, Kimura T, Takahashi S, Fujimoto Y, Ochi H, Abe H, Maekawa T, Tateno C, Yoshizato K, Chayama K.	G-to-A hypermutation in hepatitis B virus (HBV) and clinical course of patients with chronic HBV infection.	J Infect Dis	199	1599- 607	2009
Nakamoto S, <u>Imazeki F</u> , Fukai K, Fujiwara K, Arai M, Kanda T, Yonemitsu Y, Yokosuka O.	Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development.	J Hepatol	52	72-78	2009
Kanda T, Gauss- Müller V, Cordes S, Tamura R, Okitsu K, Shuang W, Nakamoto S, Fujiwara K, <u>Imazeki F</u> , Yokosuka O.	Hepatitis A virus (HAV) proteinase 3C inhibits HAV IRES-dependent translation and cleaves the polypyrimidine tract-binding protein.	J Viral Hepat			2009
Yonemitsu Y, <u>Imazeki F</u> , Chiba T, Fukai K, Nagai Y, Miyagi S, Arai M, Aoki R, Miyazaki M, Nakatani Y, Iwama A, Yokosuka O.	Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma.	Hum Pathol	40(9)	1304- 1311	2009
Kobashi H, Takaguchi K, Ikeda H, Yokosuka O, Moriyama M, <u>Imazeki F</u> , Kage M, Seriu T, Omata M, Sakaguchi K, Shiratori Y.	Efficacy and safety of entecavir in nucleoside- naive, chronic hepatitis B patients: phase II clinical study in Japan.	J Gastroenterol Hepatol	24(2)	255-261	2009

Nakamoto S, Kanda T, . Yonemitsu Y, Arai M, Fujiwara K, Fukai K, Kanai F, <u>Imazeki F</u> , Yokosuka O.	Quantification of hepatitis C amino acid substitutions 70 and 91 in the core coding region by real-time amplification refractory mutation system reverse transcription-polymerase chain reaction.	Scand J Gastroenterol	44(7)	872-827	2009
Chuma M, <u>Hige</u> S, Kamiyama T, Meguro T, Nagasaka A, Nakanishi K, Yamamoto Y, Nakanishi M, Kohara T, Sho T, Yamamoto K, Horimoto H, Kobayashi T, Yokoo H, Matsushita M, Todo S, Asaka M.	The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma.	J Gastroenterol	44	991-999	2009
Matsuura K, Tanaka Y, <u>Hige</u> S, Yamada G, Murawaki Y, Komatsu M, Kuramitsu T, Kawata S, Tanaka E, Izumi I, Okuse C, Kakumu S, Okanoue T, Hino K, Hiasa Y, Sata M, Maeshiro T, Sugauchi F, Nojiri S, Joh T, Miyakawa Y, Mizokami M.	Distribution of Hepatitis B Virus Genotypes among Patients with Chronic Infection in Japan Shifting toward an Increase of Genotype A.	J Clinical Microbiology	47	1476- 1483	2009

IV. 研究成果の刊行物・別刷